Lantheus Holdings (LNTH)
100.46
0.00 (0.00%)
Upcoming Events
Latest Headlines
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
November 2, 2026 8:30 AM - StreetInsider
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
October 30, 2026 1:53 PM - SEC Filing
Form 8-K Lantheus Holdings, Inc. For: Oct 21
October 22, 2026 7:30 AM - SEC Filing
Form 8-K Lantheus Holdings, Inc. For: Oct 14
October 14, 2026 4:31 PM - SEC Filing
Mizuho Downgrades Lantheus Holdings (LNTH) to Neutral
October 13, 2026 6:56 AM - StreetInsider
Form DEFA14A Lantheus Holdings, Inc.
October 2, 2026 5:02 PM - SEC Filing
Form 8-K Lantheus Holdings, Inc. For: Oct 02
October 2, 2026 5:01 PM - SEC Filing
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
September 30, 2026 8:30 AM - StreetInsider
Lantheus doses first patient in SPARROW prostate cancer imaging trial
September 28, 2026 8:00 AM - StreetInsider
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
September 28, 2026 8:00 AM - StreetInsider
FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs
September 22, 2026 8:01 AM - StreetInsider
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for
September 22, 2026 8:00 AM - StreetInsider
Form DEFA14A Lantheus Holdings, Inc.
September 21, 2026 4:09 PM - SEC Filing
Form 8-K Lantheus Holdings, Inc. For: Sep 17
September 21, 2026 4:06 PM - SEC Filing
Form DEFA14A Lantheus Holdings, Inc.
September 17, 2026 6:02 AM - SEC Filing
Form PREM14A Lantheus Holdings, Inc. For: Aug 26
August 26, 2026 7:20 AM - SEC Filing
Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Dinkelborg Ludger
August 19, 2026 4:34 PM - SEC Filing
Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Brown Kimberly
August 19, 2026 4:34 PM - SEC Filing
B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral
August 17, 2026 12:16 PM - StreetInsider
FDA approves Lantheus tau PET imaging agent for Alzheimer's disease
August 14, 2026 8:00 AM - StreetInsider
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
August 14, 2026 8:00 AM - StreetInsider
Form DEFA14A Lantheus Holdings, Inc.
August 13, 2026 5:20 PM - SEC Filing
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 13, 2026 5:16 PM - SEC Filing
Form 10-Q Lantheus Holdings, Inc. For: Jun 30
August 6, 2026 8:01 AM - SEC Filing
Lantheus Holdings (LNTH) Tops Q2 EPS by 26c
August 6, 2026 7:52 AM - StreetInsider
Form 8-K Lantheus Holdings, Inc. For: Aug 06
August 6, 2026 7:45 AM - SEC Filing
Lantheus Reports Second Quarter 2026 Financial Results
August 6, 2026 7:00 AM - StreetInsider
Form DEFA14A Lantheus Holdings, Inc.
August 4, 2026 4:20 PM - SEC Filing
CJS Securities Downgrades Lantheus Holdings (LNTH) to Market Perform
August 4, 2026 8:30 AM - StreetInsider
Form DEFA14A Lantheus Holdings, Inc.
August 4, 2026 6:04 AM - SEC Filing
Form 8-K Lantheus Holdings, Inc. For: Aug 01
August 4, 2026 6:04 AM - SEC Filing
Full Article List
